New drug duo aims to control hard-to-treat hodgkin lymphoma
NCT ID NCT05723055
First seen Jan 05, 2026 · Last updated Jun 18, 2026 · Updated 21 times
Summary
This study tests a combination of two drugs, nivolumab and axatilimab, in adults with classical Hodgkin lymphoma that has returned or not responded to at least one prior treatment, including anti-PD-1 therapy. The main goal is to see if the combination shrinks or controls the cancer. Nine participants are enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.